Compare FSM & HTFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FSM | HTFL |
|---|---|---|
| Founded | 1990 | 2007 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | |
| Sector | Basic Materials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.4B |
| IPO Year | N/A | 2025 |
| Metric | FSM | HTFL |
|---|---|---|
| Price | $9.97 | $30.52 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $11.00 | ★ $39.50 |
| AVG Volume (30 Days) | ★ 6.7M | 795.0K |
| Earning Date | 11-05-2025 | 02-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 809.52 | N/A |
| EPS | ★ 0.74 | N/A |
| Revenue | ★ $1,256,829,000.00 | $161,881,000.00 |
| Revenue This Year | $0.28 | $40.42 |
| Revenue Next Year | $11.27 | $22.27 |
| P/E Ratio | $12.88 | ★ N/A |
| Revenue Growth | 68.17 | ★ 85.70 |
| 52 Week Low | $4.13 | $25.38 |
| 52 Week High | $10.38 | $41.22 |
| Indicator | FSM | HTFL |
|---|---|---|
| Relative Strength Index (RSI) | 56.43 | N/A |
| Support Level | $9.22 | N/A |
| Resistance Level | $10.27 | N/A |
| Average True Range (ATR) | 0.43 | 0.00 |
| MACD | -0.06 | 0.00 |
| Stochastic Oscillator | 65.15 | 0.00 |
Fortuna Mining Corp is a Canadian-based precious metals mining company with mines in the Latin America and West Africa regions producing gold and silver. It operate mines in Argentina, Burkina Faso, Cote d'Ivoire, Mexico, and Peru. The company's segment consists of Mansfield, Sanu, Sango, Cuzcatlan, Bateas, Corporate. The company generates the majority of its revenue from Sango segment which operates the Seguela gold mine. Geographically, the company generates the majority of its revenue from Cote d'Ivoire location.
HeartFlow Inc is a commercial-stage medical technology company that has pioneered the use of software and AI to deliver a non-invasive solution for diagnosing and managing coronary artery disease CAD. The company operates and manages its business as one reportable and operating segment, which is the business of non-invasive coronary artery disease detection solutions. Geographically, it operates in United States, United Kingdom, Japan, and Rest of Europe, of which it derives maximum revenue from United States.